Juan Peris Vidal , María Ferreiro Argüelles , Rafael J. Hidalgo Urbano , Pascual Marco Vera , Antonio García Quintana , Joaquín Alonso Martín , José Antonio Vázquez de Prada Tiffe , José Mateo Arranz , Alejandro Isidoro Pérez Cabeza
{"title":"西班牙利伐沙班治疗的非瓣膜性房颤患者概况:直接口服抗凝药物的不平等获得(HEROIC研究)","authors":"Juan Peris Vidal , María Ferreiro Argüelles , Rafael J. Hidalgo Urbano , Pascual Marco Vera , Antonio García Quintana , Joaquín Alonso Martín , José Antonio Vázquez de Prada Tiffe , José Mateo Arranz , Alejandro Isidoro Pérez Cabeza","doi":"10.1016/j.carcor.2018.04.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Restrictions on the prescription of direct oral anticoagulants (DOACs) for non-valvular atrial fibrillation (NVAF) treatment imposed in Spain by the 2013 Therapeutic Positioning Report (TPR) may limit access to this medication. With the aim of assessing the impact of the TPR, we analysed the reasons to prescribe the DOAC rivaroxaban, the profile of patients with NVAF treated and how long it takes accessing to the treatment in hospitals belonging to the National Health System, both overall and by autonomous regions.</p></div><div><h3>Methods</h3><p>An observational, cross-sectional, multicenter study of patients with NVAF treated with rivaroxaban in specialist practice. The autonomous regions were grouped according to the most common prescribing practices: per Summary of Product Characteristics (SmPC), TPR or a more restrictive or modified TPR (mTPR).</p></div><div><h3>Results</h3><p>73 researchers providing data on 1,727 patients participated. 93.7% of patients were at high thromboembolic risk (CHA<sub>2</sub>DS<sub>2</sub>-Vasc ≥<!--> <!-->3) and 46.2% were at high risk for bleeding (HAS-BLED ≥<!--> <!-->3). Median time since diagnosis of NVAF for receiving rivaroxaban was 21.1<!--> <!-->months. 57.0% patients had received vitamin<!--> <!-->K antagonists (VKA). With respect to autonomous regions where prescribing practices are guided by SmPC, patients where TPR/mTPR restrictions were followed were at higher thromboembolic and bleeding risk, had received VKA more frequently and waited a median of ∼<!--> <!-->20<!--> <!-->months longer before receiving rivaroxaban.</p></div><div><h3>Conclusions</h3><p>Patients treated with rivaroxaban in Spain show high thromboembolic and bleeding risks. Median time for rivaroxaban prescription is 21.1<!--> <!-->months. The differences in the adhesion to the TPR create inequalities between autonomous regions. Patients from autonomous regions following the TPR/mTPR receive rivaroxaban up to 20<!--> <!-->months later and show higher thromboembolic and bleeding risks.</p></div>","PeriodicalId":100216,"journal":{"name":"Cardiocore","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"Perfil de pacientes con fibrilación auricular no valvular tratados con rivaroxaban en España: la desigualdad en el acceso a los anticoagulantes orales directos (estudio HEROIC)\",\"authors\":\"Juan Peris Vidal , María Ferreiro Argüelles , Rafael J. Hidalgo Urbano , Pascual Marco Vera , Antonio García Quintana , Joaquín Alonso Martín , José Antonio Vázquez de Prada Tiffe , José Mateo Arranz , Alejandro Isidoro Pérez Cabeza\",\"doi\":\"10.1016/j.carcor.2018.04.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and objectives</h3><p>Restrictions on the prescription of direct oral anticoagulants (DOACs) for non-valvular atrial fibrillation (NVAF) treatment imposed in Spain by the 2013 Therapeutic Positioning Report (TPR) may limit access to this medication. With the aim of assessing the impact of the TPR, we analysed the reasons to prescribe the DOAC rivaroxaban, the profile of patients with NVAF treated and how long it takes accessing to the treatment in hospitals belonging to the National Health System, both overall and by autonomous regions.</p></div><div><h3>Methods</h3><p>An observational, cross-sectional, multicenter study of patients with NVAF treated with rivaroxaban in specialist practice. The autonomous regions were grouped according to the most common prescribing practices: per Summary of Product Characteristics (SmPC), TPR or a more restrictive or modified TPR (mTPR).</p></div><div><h3>Results</h3><p>73 researchers providing data on 1,727 patients participated. 93.7% of patients were at high thromboembolic risk (CHA<sub>2</sub>DS<sub>2</sub>-Vasc ≥<!--> <!-->3) and 46.2% were at high risk for bleeding (HAS-BLED ≥<!--> <!-->3). Median time since diagnosis of NVAF for receiving rivaroxaban was 21.1<!--> <!-->months. 57.0% patients had received vitamin<!--> <!-->K antagonists (VKA). With respect to autonomous regions where prescribing practices are guided by SmPC, patients where TPR/mTPR restrictions were followed were at higher thromboembolic and bleeding risk, had received VKA more frequently and waited a median of ∼<!--> <!-->20<!--> <!-->months longer before receiving rivaroxaban.</p></div><div><h3>Conclusions</h3><p>Patients treated with rivaroxaban in Spain show high thromboembolic and bleeding risks. Median time for rivaroxaban prescription is 21.1<!--> <!-->months. The differences in the adhesion to the TPR create inequalities between autonomous regions. Patients from autonomous regions following the TPR/mTPR receive rivaroxaban up to 20<!--> <!-->months later and show higher thromboembolic and bleeding risks.</p></div>\",\"PeriodicalId\":100216,\"journal\":{\"name\":\"Cardiocore\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiocore\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1889898X18300306\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiocore","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1889898X18300306","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Perfil de pacientes con fibrilación auricular no valvular tratados con rivaroxaban en España: la desigualdad en el acceso a los anticoagulantes orales directos (estudio HEROIC)
Introduction and objectives
Restrictions on the prescription of direct oral anticoagulants (DOACs) for non-valvular atrial fibrillation (NVAF) treatment imposed in Spain by the 2013 Therapeutic Positioning Report (TPR) may limit access to this medication. With the aim of assessing the impact of the TPR, we analysed the reasons to prescribe the DOAC rivaroxaban, the profile of patients with NVAF treated and how long it takes accessing to the treatment in hospitals belonging to the National Health System, both overall and by autonomous regions.
Methods
An observational, cross-sectional, multicenter study of patients with NVAF treated with rivaroxaban in specialist practice. The autonomous regions were grouped according to the most common prescribing practices: per Summary of Product Characteristics (SmPC), TPR or a more restrictive or modified TPR (mTPR).
Results
73 researchers providing data on 1,727 patients participated. 93.7% of patients were at high thromboembolic risk (CHA2DS2-Vasc ≥ 3) and 46.2% were at high risk for bleeding (HAS-BLED ≥ 3). Median time since diagnosis of NVAF for receiving rivaroxaban was 21.1 months. 57.0% patients had received vitamin K antagonists (VKA). With respect to autonomous regions where prescribing practices are guided by SmPC, patients where TPR/mTPR restrictions were followed were at higher thromboembolic and bleeding risk, had received VKA more frequently and waited a median of ∼ 20 months longer before receiving rivaroxaban.
Conclusions
Patients treated with rivaroxaban in Spain show high thromboembolic and bleeding risks. Median time for rivaroxaban prescription is 21.1 months. The differences in the adhesion to the TPR create inequalities between autonomous regions. Patients from autonomous regions following the TPR/mTPR receive rivaroxaban up to 20 months later and show higher thromboembolic and bleeding risks.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
